Anti-Hu CD253 Purified

Anti-Hu CD253 Purified
Regulatory status
RUO
Antigen
CD253
Clone
2E5
Format
Purified
Reactivity
Human
Application
FC (QC tested)
Variant
0.1 mg
11-316-C100
In stock
130.00 USD

0.025 mg
11-316-C025
Out of stock
65.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD

0.1 mg
11-261-C100
In stock
65.00 USD
Product details
References
Isotype
Mouse IgG1
Specificity
The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.
Workshop
HLDA X
Application
FC (QC tested)
Reactivity
Human
Negative species
Mouse
Immunogen
Recombinant soluble fragment (aa 95-281) of human TRAIL.
Other names
TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Product specific references:

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC: Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005 Jun 1;65(11):4799-808.
PubMed
Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002 Jan;16(1):67-73.
PubMed
Variant
0.1 mg
11-316-C100
In stock
130.00 USD

0.025 mg
11-316-C025
Out of stock
65.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD

0.1 mg
11-261-C100
In stock
65.00 USD